Indaptus Therapeutics, Inc. — 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a standalone fourth-quarter report. The August 2021 merger with Decoy was accounted for as a reverse merger; Decoy’s historical financial statements became the combined company’s historical statements. Comparisons with 2020 should therefore be interpreted in light of the transaction and the change in business focus.
Business context and material developments
Indaptus is a preclinical biotechnology company developing systemically administered immunotherapies using attenuated, killed Gram-negative bacteria intended to activate innate and adaptive immune responses. Its lead candidate, Decoy20, had completed GMP manufacturing and reported IND-enabling work by year-end. The company had no approved or commercialized products and reported no revenue.
- Indaptus completed its domestication merger in July and its merger with Decoy on August 3, 2021. Decoy became the wholly owned subsidiary and the principal business.
- Following the merger, the company wound down Intec Israel’s Accordion Pill business, including employee layoffs and termination of related contracts.
- A July 2021 private placement generated approximately $27.3 million in net proceeds. The pre-funded warrants were exercised in September; associated warrants remained outstanding.
- As of March 1, 2022, the company reported 33 granted patents and 16 pending patent applications.
Financial performance and position
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $2.52 million | $2.66 million |
| General and administrative expense | $5.21 million | $0.94 million |
| Total operating expenses / operating loss | $7.73 million | $3.60 million |
| Net loss | $7.71 million | $3.58 million |
| Net loss per share, basic and diluted | $1.89 | $1.84 |
| Net cash used in operating activities | $11.29 million | $3.32 million |
| Cash and cash equivalents at year-end | $39.13 million | $1.64 million |
- Net loss increased 115% year over year. R&D expense declined about 5%, while G&A rose substantially, mainly reflecting higher payroll, stock-based compensation, professional fees, and public-company costs.
- Cash from financing activities was $48.34 million, including private-placement proceeds, merger-related proceeds, and $5.0 million from SAFEs. Investing activities provided $0.45 million, primarily from asset-sale proceeds.
- At December 31, 2021, total assets were $40.58 million, total liabilities $4.68 million, and stockholders’ equity $35.90 million. Current assets were $40.39 million versus current liabilities of $4.60 million. The filing reports no material off-balance-sheet arrangements and no conventional borrowings in the presented balance sheet.
- The company recorded an accumulated deficit of $15.67 million and $1.51 million of stock-based compensation expense. Its financial statements received an unqualified audit opinion; the auditor highlighted the determination of the accounting acquirer as a critical audit matter.
Outlook, risks, and contingencies
As of the filing, management planned to submit an IND for Decoy20 in the first half of 2022 and initiate a Phase 1 trial in 2022 in patients with solid tumors. The proposed program included dose escalation and expansion, with potential later combination testing. These were plans, not reported achievements. Management stated that available cash was expected to fund operations for more than one year from the filing date, while also stating that substantial additional financing would be needed to advance development and commercialization.
- The company is preclinical, unprofitable, and dependent on successful development of Decoy20. Clinical safety, efficacy, regulatory review, and timelines remain uncertain.
- Management disclosed reliance on third parties for research, trials, and manufacturing, as well as risks of supply disruption, manufacturing failures, trial delays, and increased costs.
- COVID-19 had already lengthened the GMP process; the filing also cited possible effects on operations, regulators, and access to capital. Management identified market uncertainty related to Russia’s invasion of Ukraine.
- The company stated that capital may not be available on acceptable terms; additional equity could dilute shareholders, while debt or collaborations could impose restrictions or require relinquishing rights.
- There were no pending material legal proceedings reported as of March 16, 2022. The company had a $178,852 operating lease commitment at year-end, including $96,465 due in 2022. It reported a full valuation allowance against deferred tax assets; use of tax-loss carryforwards may be limited, including by ownership-change rules.
- Management concluded disclosure controls and internal control over financial reporting were effective as of year-end. The auditor did not attest to internal controls, consistent with the company’s reporting status.
Most important facts for investors to verify
- Whether the Decoy20 IND was filed and cleared, and whether the planned Phase 1 trial began on schedule.
- Cash runway against actual operating cash use, trial costs, and the need and terms of future financing.
- Potential dilution: 3,090,787 warrants and 1,174,660 options were outstanding at December 31, 2021; verify current balances and terms.
- Clinical evidence supporting the preclinical claims, especially human safety and efficacy and the risk of immune-related adverse effects.
- Whether manufacturing and third-party arrangements can reliably support clinical supply, and whether merger-related reporting comparisons reflect the reverse-merger accounting.